Embecta Corp. $EMBC Shares Sold by Jacobs Levy Equity Management Inc.

Key Points

• Jacobs Levy Equity Management Inc. reduced its holdings in Embecta Corp. by 61.7% in the first quarter, now owning approximately 0.07% of the company valued at $537,000.
• Embecta has received a mix of ratings from analysts, with a consensus price target of $19.00 and ratings ranging from "Strong Buy" to "Hold."
• The company reported earnings of $1.12 per share for the last quarter, exceeding estimates, and has announced a quarterly dividend of $0.15 per share with a yield of 4.0%.

Jacobs Levy Equity Management Inc. lowered its stake in Embecta Corp. (NASDAQ:EMBC - Free Report) by 61.7% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 42,108 shares of the company's stock after selling 67,786 shares during the period. Jacobs Levy Equity Management Inc. owned 0.07% of Embecta worth $537,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in EMBC. Banque Transatlantique SA grew its stake in shares of Embecta by 879.1% in the 1st quarter. Banque Transatlantique SA now owns 3,701 shares of the company's stock worth $44,000 after buying an additional 3,323 shares during the last quarter. Brooklyn Investment Group boosted its stake in Embecta by 1,164.1% during the 1st quarter. Brooklyn Investment Group now owns 3,590 shares of the company's stock valued at $46,000 after purchasing an additional 3,306 shares during the last quarter. Wealthquest Corp purchased a new position in shares of Embecta in the 1st quarter worth $48,000. Picton Mahoney Asset Management purchased a new position in shares of Embecta in the 1st quarter worth $50,000. Finally, Ameriflex Group Inc. purchased a new position in shares of Embecta in the 4th quarter worth $53,000. Hedge funds and other institutional investors own 93.83% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on EMBC shares. Zacks Research upgraded Embecta from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 26th. Wall Street Zen upgraded Embecta from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Mizuho dropped their price target on Embecta from $13.00 to $12.00 and set a "neutral" rating on the stock in a research note on Wednesday, July 16th. Finally, BTIG Research restated a "buy" rating and issued a $25.00 price target on shares of Embecta in a research note on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Embecta currently has a consensus rating of "Moderate Buy" and an average price target of $19.00.

Embecta Trading Up 0.7%

Shares of NASDAQ EMBC traded up $0.11 during trading hours on Thursday, reaching $15.17. The stock had a trading volume of 385,671 shares, compared to its average volume of 481,156. The firm has a market cap of $887.29 million, a price-to-earnings ratio of 10.61, a P/E/G ratio of 0.84 and a beta of 1.12. The business's fifty day moving average price is $12.75 and its two-hundred day moving average price is $11.97. Embecta Corp. has a 52-week low of $9.20 and a 52-week high of $21.48.

Embecta (NASDAQ:EMBC - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.77 by $0.35. The firm had revenue of $295.50 million during the quarter, compared to analyst estimates of $278.15 million. Embecta had a negative return on equity of 23.40% and a net margin of 7.58%.Embecta's quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.74 earnings per share. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. Equities research analysts anticipate that Embecta Corp. will post 2.85 earnings per share for the current fiscal year.

Embecta Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 15th. Investors of record on Friday, August 29th were paid a $0.15 dividend. The ex-dividend date of this dividend was Friday, August 29th. This represents a $0.60 dividend on an annualized basis and a yield of 4.0%. Embecta's payout ratio is 41.96%.

Embecta Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.